The activity of eupafolin in the treatment of skin inflammatory diseases in the molecular dimension is expressed in the form of suppression of intracellular ROS generation, NK-κB activation, cyclooxygenase-2 (COX-2) protein and gene expression, and prostaglandin E2 (PGE2) production in HaCaT cells. The gene discussed is PTGS2; the disease is inflammatory skin disease.